EFNB2 ephrin B2
ENSG00000125266 · protein coding · Open Targets profile
Cell surface transmembrane ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Binds to receptor tyrosine kinase including EPHA4, EPHA3 and EPHB4. Together with EPHB4 plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. EPHB4-mediated forward signaling controls cellular repulsion and segregation from EFNB2-expressing cells. May play a role in constraining the orientation of longitudinally projecting axons. .
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- High-Quality Pocket
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Database Ubiquitination, Half-life Data
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.15591999888420105 (upper bound 0.32784000039100647). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 9 registry trials, updated in the last three years, of the most advanced drugs against EFNB2 (SEPHB4-HSA), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Sarmad SadeghiUniversity of Southern California · 3 of 3 trials Phase 2+
- Carl MillnerAIDS Healthcare Foundation · 1 of 1 trials Phase 2+
- Casey O'ConnellUniversity of Southern California · 1 of 1 trials Phase 2+
- Ida Wong-SefidanAIDS Malignancy Consortium · 1 of 1 trials Phase 2+
- Jorge NievaUniversity of Southern California · 1 of 1 trials Phase 2+
- Anthony El-KhoueiryUniversity of Southern California · 0 of 1 trials Phase 2+
Registry trials of SEPHB4-HSA updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 9 of 9 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
5 trials of drugs against EFNB2 were stopped early
Terminated, withdrawn and suspended interventional trials of SEPHB4-HSA, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 5 most recent of 5.
- terminated · 2026-06-08 · University of Southern California · matched by the registry's drug synonyms“Lack of funding”
- withdrawn · 2023-06-26 · University of Southern California · matched by the registry's drug synonyms“Budget issues”
- terminated · 2022-08-24 · University of Southern California · recombinant albumin fusion protein sEphB4-HSA“Lack of funding”
- terminated · 2021-11-30 · University of Southern California · matched by the registry's drug synonyms“Study drug supply issue”
- terminated · 2021-11-24 · University of Southern California · matched by the registry's drug synonyms“Insufficient accrual”
Paediatric incentives and obligations for EFNB2's drugs
For SEPHB4-HSA: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · EFNB2 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names sephb4-hsaRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names sephb4-hsaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of sephb4-hsaRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of sephb4-hsaRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: no · No interventional study of sephb4-hsa includes patients under 18Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 1 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| SEPHB4-HSA | Unknown | phase 2 3 | Kaposi's sarcoma, prostate cancer, urothelial carcinoma, non-small cell lung carcinoma, myelodysplastic syndrome, acute myeloid leukemia, glioma, lung cancer, +14 more | Open Targets · ChEMBL |